Xplocid-SR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders associated with acid reflux and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation of Xplocid-SR ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance. This combination is particularly beneficial in patients requiring both acid suppression and prokinetic effects to manage complex upper gastrointestinal symptoms. Xplocid-SR should be administered under medical supervision, considering contraindications such as known hypersensitivity to its components and caution in patients with cardiac arrhythmias or hepatic impairment. Regular monitoring is advised to assess therapeutic efficacy and detect potential adverse effects.